# Expanded Access to Mepsevii

> **NCT03775174** · — · AVAILABLE · sponsor: **Ultragenyx Pharmaceutical Inc**

## Conditions studied

- MPS VII
- Mucopolysaccharidosis VII
- Sly Syndrome

## Interventions

- **DRUG:** Mepsevii

## Key facts

- **NCT ID:** NCT03775174
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03775174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03775174, "Expanded Access to Mepsevii". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03775174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*